ANN ARBOR, Mich., Oct. 12, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today that George J. Brewer, M.D., the Company's Senior Vice President of Research & Development, will be a featured speaker at the 2011 International Society for Trace Element Research in Humans Conference to be held in Belek, Turkey, on October 16-21, 2011. Dr. Brewer is the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.
During the plenary session "Distinguished Scientist of the World: George J. Brewer, M.D.", Dr. Brewer will discuss the role of zinc deficiency and copper toxicity on cognitive loss and their contributions to the current epidemic of Alzheimer's disease. Dr. Brewer will also Co-Chair the plenary session "Fifty Years of the Miracle Element Zinc" with Ananda S. Prasad, M.D., Ph.D., a Distinguished Professor of Internal Medicine at Wayne State University School of Medicine and an Adeona Scientific Advisory Board member. During this plenary session, Dr. Brewer will discuss zinc therapy for Wilson's disease and Alzheimer's disease.
About International Society for Trace Element Research in Humans
The International Society for Trace Element Research in Humans was founded in 1984 as a non-profit corporation to: 1) encourage and promote increased scientific and clinical research on the causes, alleviation of suffering and the cure of trace element disorders; 2) accumulate information about trace elements, and promote its dissemination to scientists and physicians and other concerned parties; and 3) educate the general public and medical profession about the existence, diagnosis and treatment of trace element disorders. For more information about International Society for Trace Element Research in Humans, please visit the website at www.isterh.com.
About Adeona Pharmaceuticals, Inc.
Adeona is a pharmaceutical company focused on developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Adeona is developing, or has partnered the development of, drug product candidates to treat multiple sclerosis, fibromyalgia, amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. The Company is currently preparing to make the following products commercially available: reaZin™, a prescription medical food for the dietary management of zinc deficiency associated with Alzheimer's disease, and wellZin™, a homeopathic over-the-counter medicine for reducing the duration and symptoms of the common cold. Adeona also operates Adeona Clinical Laboratory, a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com.
SOURCE Adeona Pharmaceuticals, Inc.